Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Inhibrx Biosciences (INBX) Receivables - Net (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Receivables - Net for 3 consecutive years, with $23000.0 as the latest value for Q4 2025.

  • Quarterly Receivables - Net fell 88.5% to $23000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23000.0 through Dec 2025, down 88.5% year-over-year, with the annual reading at $23000.0 for FY2025, 88.5% down from the prior year.
  • Receivables - Net for Q4 2025 was $23000.0 at Inhibrx Biosciences, down from $237000.0 in the prior quarter.
  • The five-year high for Receivables - Net was $778000.0 in Q4 2023, with the low at $23000.0 in Q4 2025.
  • Average Receivables - Net over 3 years is $345666.7, with a median of $218500.0 recorded in 2024.
  • Peak annual rise in Receivables - Net hit 44.51% in 2025, while the deepest fall reached 88.5% in 2025.
  • Over 3 years, Receivables - Net stood at $778000.0 in 2023, then tumbled by 74.29% to $200000.0 in 2024, then plummeted by 88.5% to $23000.0 in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $23000.0, $237000.0, and $200000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.